{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:33:43Z","timestamp":1786361623290,"version":"build-2736575974"},"reference-count":350,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite advances in first-line therapy, a subset of breast cancer patients\u2014particularly those with triple-negative breast cancer (TNBC)\u2014continue to experience unfavorable prognosis. Recently, the addition of neoadjuvant immunotherapy has been intensively studied and widely adopted to improve clinical outcomes of patients with breast cancer. Based on encouraging results from large-scale clinical trials such as KEYNOTE-522 and IMpassion031, the range of drugs evaluated has expanded from atezolizumab to other programmed cell death protein 1\/programmed cell death-ligand 1(PD-1\/PD-L1) inhibitors, such as pembrolizumab and avelumab. Furthermore, the pursuit of targeted therapies has extended to other biomarkers, including Forkhead Box Protein P3 (FOXP3) and Wilms\u2019 Tumor gene 1 (WT1). Despite these advancements, the heterogeneity in trial design, participant demographics, endpoints, and other confounding variables has resulted in divergent conclusions across clinical studies. In this review, we delineate the principal neoadjuvant immunotherapy biomarkers implicated in breast cancer and elucidate their action mechanisms. We also summarize the ongoing and reported clinical studies, aiming to offer a coherent perspective on the evolving role of neoadjuvant immunotherapy in breast cancer management.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1851289","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:09:14Z","timestamp":1786360154000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarker-driven neoadjuvant immunotherapy in triple-negative breast cancer: emerging therapeutic targets FOXP3 and WT1"],"prefix":"10.3389","volume":"17","author":[{"given":"Ziwei","family":"Zhang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, Department of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, Department of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Urinary Disease Center Nursing, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"West China School of Nursing, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery and Orthopedic Research Institution, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, Department of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefan","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, Department of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Ding","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, Department of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manni","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, Department of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: presentation, investigation and management","volume":"83","author":"K","year":"2022","journal-title":"Br J Hosp Med (Lond)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.60631","article-title":"Progress of breast cancer basic research in China","volume":"17","author":"W","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0266-x","article-title":"Key steps for effective breast cancer prevention","volume":"20","author":"B","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"S","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"20211033","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"W","year":"2022","journal-title":"Br J Radiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"B","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B7","article-title":"Breast cancer treatment","volume":"104","author":"Trayes","year":"2021","journal-title":"Am Fam Phys"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz213","article-title":"Adjuvant and neoadjuvant therapy for breast cancer","volume":"50","author":"Shien","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/gco.0000000000000147","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7016","article-title":"The evolving role of neoadjuvant therapy for operable breast cancer","volume":"20","author":"Spring","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12358","article-title":"Breast cancer: an up-to-date review and future perspectives","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2020.1147","article-title":"Neoadjuvant immunotherapy in breast cancer: a paradigm shift","volume":"14","author":"Fountzila","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"B14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41571-020-00440-6","article-title":"Neoadjuvant therapy improves pCR rate","volume":"17","author":"Sidaway","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.3390\/cancers14174064","article-title":"Updated neoadjuvant treatment landscape for early triple negative breast cancer: immunotherapy, potential predictive biomarkers, and novel agents","volume":"14","author":"Garufi","year":"2022","journal-title":"Cancers (Bsl)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103223","article-title":"Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials","volume":"159","author":"Tarantino","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/cancers14030521","article-title":"Pathological response in the breast and axillary lymph nodes after neoadjuvant systemic treatment in patients with initially node-positive breast cancer correlates with disease free survival: an exploratory analysis of the GeparOcto trial","volume":"14","author":"Gerber","year":"2022","journal-title":"Cancers (Bsl)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.10.011","article-title":"Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer","volume":"160","author":"Schneeweiss","year":"2022","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/cco.2020.01.06","article-title":"Biomarkers of neoadjuvant\/adjuvant chemotherapy for breast cancer","volume":"9","author":"Iwamoto","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02501-w","article-title":"Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis","volume":"130","author":"Cunha","year":"2024","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"a041332","DOI":"10.1101\/cshperspect.a041332","article-title":"Immunotherapy approaches for breast cancer patients in 2023","volume":"13","author":"Emens","year":"2023","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad233","article-title":"The evolving landscape of immune checkpoint inhibitors and antibody drug conjugates in the treatment of early-stage breast cancer","volume":"28","author":"Bhardwaj","year":"2023","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3255","article-title":"Current panorama and challenges for neoadjuvant cancer immunotherapy","volume":"26","author":"Benitez","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/cells10020223","article-title":"Immune infiltrates in breast cancer: recent updates and clinical implications","volume":"10","author":"Dieci","year":"2021","journal-title":"Cells"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00386-1","article-title":"Immunotherapy for early triple negative breast cancer: research agenda for the next decade","volume":"8","author":"Tarantino","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31962-0","article-title":"Advancing immunotherapy for early-stage triple-negative breast cancer","volume":"396","author":"Di Cosimo","year":"2020","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.003","article-title":"Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment","author":"Agostinetto","year":"2024","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0583","article-title":"Facts and hopes in neoadjuvant immunotherapy: current approvals and emerging evidence","volume":"30","author":"Vaidya","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.00319-13","article-title":"PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2","volume":"33","author":"Patsoukis","year":"2013","journal-title":"Mol Cell Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S190432","article-title":"Anticancer activity of 1,25-(OH)(2)D(3) against human breast cancer cell lines by targeting Ras\/MEK\/ERK pathway","volume":"12","author":"Zheng","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett"},{"key":"B35","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1038\/s41467-022-34346-x","article-title":"Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation","volume":"13","author":"Shi","year":"2022","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-021-01447-y","article-title":"METTL3\/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer","volume":"21","author":"Wan","year":"2022","journal-title":"Mol Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.03.039","article-title":"Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR","volume":"11","author":"Liu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110260","article-title":"Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer","volume":"369","author":"Zhou","year":"2023","journal-title":"Chem Biol Interact"},{"key":"B40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/imr.12525","article-title":"Immunoregulatory functions of VISTA","volume":"276","author":"Nowak","year":"2017","journal-title":"Immunol Rev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","article-title":"Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T cell exhaustion","volume":"11","author":"Peng","year":"2020","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.656190","article-title":"FOXP3 inhibits the metastasis of breast cancer by downregulating the expression of MTA1","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.05.042","article-title":"FOXP3 controls regulatory T cell function through cooperation with NFAT","volume":"126","author":"Wu","year":"2006","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00428-016-2045-3","article-title":"CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma","volume":"470","author":"Sanmart\u00edn","year":"2017","journal-title":"Virchows Arch"},{"key":"B45","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41419-018-0790-8","article-title":"Foxp3 inhibits angiogenesis by downregulating vegf in breast cancer","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3892\/or.2023.8497","article-title":"Laptm5 regulated by foxp3 promotes the Malignant phenotypes of breast cancer through activating the wnt\/\u03b2-catenin pathway","volume":"49","author":"Han","year":"2023","journal-title":"Oncol Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25523","article-title":"Foxp3 and mir-155 cooperate to control the invasive potential of human breast cancer cells by down regulating zeb2 independently of zeb1","volume":"9","author":"Brown","year":"2018","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2022.113035","article-title":"Ckap2l, transcriptionally inhibited by foxp3, promotes breast carcinogenesis through the akt\/mtor pathway","volume":"412","author":"Chi","year":"2022","journal-title":"Exp Cell Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/path.4381","article-title":"Breast cancer metastasis: demonstration that foxp3 regulates cxcr4 expression and the response to cxcl12","volume":"234","author":"Douglass","year":"2014","journal-title":"J Pathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6771","article-title":"Runx1 and foxp3 interplay regulates expression of breast cancer related genes","volume":"7","author":"Recouvreux","year":"2016","journal-title":"Oncotarget"},{"key":"B51","article-title":"Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells","volume":"28","author":"Zang","year":"2008","journal-title":"Anticancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2741\/3862","article-title":"Wt1\/egr1-mediated control of stim1 expression and function in cancer cells","volume":"16","author":"Ritchie","year":"2011","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1159\/000464353","article-title":"PD-1\/PD-L1 pathway in breast cancer","volume":"40","author":"Sch\u00fctz","year":"2017","journal-title":"Oncol Res Treat"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/or.2020.7831","article-title":"PD-L1\/PD-1 blockade in breast cancer: the immunotherapy era (review)","volume":"45","author":"Li","year":"2021","journal-title":"Oncol Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30167-x","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0056","article-title":"SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K\/AKT\/GSK3\u03b2 signaling pathway","volume":"17","author":"Yuan","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-022-00698-1","article-title":"A comprehensive review of SHP2 and its role in cancer","volume":"45","author":"Asmamaw","year":"2022","journal-title":"Cell Oncol (Dordr)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Tgt Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.c.6769326.v2","article-title":"PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells","volume":"83","author":"Exposito","year":"2023","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"11444","DOI":"10.1038\/s41598-022-15020-0","article-title":"PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020104514","article-title":"m(6) A RNA methyltransferases METTL3\/14 regulate immune responses to anti-PD-1 therapy","volume":"39","author":"Wang","year":"2020","journal-title":"EMBO J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"djw283","DOI":"10.4049\/jimmunol.198.supp.56.4","article-title":"The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion","volume":"109","author":"Lu","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00766-z","article-title":"Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria","volume":"33","author":"Xie","year":"2023","journal-title":"Cell Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/ijms18071566","article-title":"New insights into the role of autophagy in tumor immune microenvironment","volume":"18","author":"Li","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"eaav3334","DOI":"10.1126\/scisignal.aav3334","article-title":"Tumor-derived TGF-\u03b2 inhibits mitochondrial respiration to suppress IFN-\u03b3 production by human CD4(+) T cells","volume":"12","author":"Dimeloe","year":"2019","journal-title":"Sci Signal"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30289","article-title":"Impaired T cell function in Malignant pleural effusion is caused by TGF-\u03b2 derived predominantly from macrophages","volume":"139","author":"Li","year":"2016","journal-title":"Int J Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612920114","article-title":"COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells","volume":"114","author":"Prima","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B77","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2018.09.007","article-title":"Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages","volume":"175","author":"Su","year":"2018","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117437","article-title":"PD-L1\/PD-1 axis as a potent therapeutic target in breast cancer","volume":"247","author":"Bastaki","year":"2020","journal-title":"Life Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.12.003","article-title":"PD-L1 status in breast cancer: Current view and perspectives","volume":"72","author":"Vranic","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbcan.2017.10.007","article-title":"Triple negative breast cancer: Key role of tumor-associated macrophages in regulating the activity of anti-PD-1\/PD-L1 agents","volume":"1869","author":"Santoni","year":"2018","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01786-6","article-title":"Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8(+) T cell exclusion","volume":"40","author":"Fang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41419-021-03745-1","article-title":"Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1(-)PD-L1(+) Bregs through PD-L1\/PI3K\/AKT\/NF-\u03baB axis in breast cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13520","article-title":"Human FOXP3 and tumour microenvironment","volume":"168","author":"Wang","year":"2023","journal-title":"Immunology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4419-1599-3_2","article-title":"FOXP3 and its role in the immune system","volume":"665","author":"Kim","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-012-9395-3","article-title":"The role of FOXP3 in the development and metastatic spread of breast cancer","volume":"31","author":"Douglass","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110015","article-title":"Complexity and diversity of FOXP3 isoforms: Novel insights into the regulation of the immune response in metastatic breast cancer","volume":"118","author":"Malla","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-2108","article-title":"FOXP3 controls an miR-146\/NF-\u03baB negative feedback loop that inhibits apoptosis in breast cancer cells","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.07.036","article-title":"FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2\/ErbB2 oncogene","volume":"129","author":"Zuo","year":"2007","journal-title":"Cell"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-6-19","article-title":"Foxp3 expression in human cancer cells","volume":"6","author":"Karanikas","year":"2008","journal-title":"J Transl Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3233\/bd-239002","article-title":"FOXP3 regulatory T cells on prognosis of breast cancer","volume":"42","author":"Usman","year":"2023","journal-title":"Breast Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07017-8","article-title":"The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3\u2009+\u2009and CD8\u2009+) and tumor-associated macrophages in early HER2\u2009+\u2009breast cancer","volume":"201","author":"J\u00e4\u00e4skel\u00e4inen","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.s454421","article-title":"The potential of FOXP3 in predicting survival and treatment response in breast cancer","volume":"17","author":"Liu","year":"2024","journal-title":"Int J Gen Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1186\/s12885-016-2732-0","article-title":"Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis","volume":"16","author":"Shou","year":"2016","journal-title":"BMC Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2017.01.011","article-title":"High tumor-infiltrating FoxP3(+) T cells predict poor survival in estrogen receptor-positive breast cancer: A meta-analysis","volume":"43","author":"Qian","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00605","article-title":"Regulatory T cell and forkhead box protein 3 as modulators of immune homeostasis","volume":"8","author":"Pereira","year":"2017","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.883560","article-title":"Role of cytokines in thymic regulatory T cell generation: Overview and updates","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2018.12.004","article-title":"The expression of FOXP3 and its role in human cancers","volume":"1871","author":"Jia","year":"2019","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B100","first-page":"14608","article-title":"Expression of tumoral FOXP3 in gastric adenocarcinoma is associated with favorable clinicopathological variables and related with Hippo pathway","volume":"8","author":"Suh","year":"2015","journal-title":"Int J Clin Exp Path"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982986","article-title":"FOXP3+ regulatory T cells and the immune escape in solid tumours","volume":"13","author":"Qiu","year":"2022","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075043","article-title":"Induced CD4+Foxp3+ regulatory T cells in immune tolerance","volume":"30","author":"Bilate","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.004","article-title":"Chemokines and cancer: New immune checkpoints for cancer therapy","volume":"51","author":"Karin","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02362.x","article-title":"Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression","volume":"118","author":"Oderup","year":"2006","journal-title":"Immunology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401936","article-title":"PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells","volume":"194","author":"Park","year":"2015","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e4","article-title":"Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy","volume":"20","author":"Kim","year":"2020","journal-title":"Immune Netw"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00216","article-title":"Regulatory T-cell-mediated suppression of conventional T-cells and dendritic cells by different cAMP intracellular pathways","volume":"7","author":"Rueda","year":"2016","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750542","article-title":"Regulatory t cells: regulation of identity and function","volume":"12","author":"Grover","year":"2021","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.10","article-title":"Foxp3+ regulatory t cells and their functional regulation","volume":"12","author":"Li","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.3390\/ijms19072036","article-title":"Foxp3 activates sumo-conjugating ubc9 gene in mcf7 breast cancer cells","volume":"19","author":"Wang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1172\/jci32538","article-title":"Foxp3 is a novel transcriptional repressor for the breast cancer oncogene skp2","volume":"117","author":"Zuo","year":"2007","journal-title":"J Clin Invest"},{"key":"B112","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3892\/ol.2020.12155","article-title":"Forkhead box p3 promotes breast cancer cell apoptosis by regulating programmed cell death 4 expression","volume":"20","author":"Fan","year":"2020","journal-title":"Oncol Lett"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29482","article-title":"Foxp3 suppresses breast cancer metastasis through downregulation of cd44","volume":"137","author":"Zhang","year":"2015","journal-title":"Int J Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13058-017-0858-x","article-title":"Microrna-200c and microrna- 141 are regulated by a foxp3-kat2b axis and associated with tumor metastasis in breast cancer","volume":"19","author":"Zhang","year":"2017","journal-title":"Breast Cancer Res"},{"key":"B115","article-title":"Foxp3+ cells recruited by ccl22 into breast cancer correlates with less tumor nodal infiltration","volume":"36","author":"Freier","year":"2016","journal-title":"Anticancer Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/v15091813","article-title":"Targeting foxp3 tumor-intrinsic effects using adenoviral vectors in experimental breast cancer","volume":"15","author":"Nicola Candia","year":"2023","journal-title":"Viruses"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.2010.22.030","article-title":"Targeting foxp3+ regulatory t cells-related immunosuppression for cancer immunotherapy","volume":"123","author":"Feng","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00292","article-title":"How numbers, nature, and immune status of foxp3(+) regulatory t-cells shape the early immunological events in tumor development","volume":"4","author":"Darrasse-J\u00e8ze","year":"2013","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.04.008","article-title":"Regulatory t cells and treatment of cancer","volume":"20","author":"Curiel","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B120","article-title":"Targeting cd4+cd25+foxp3+ regulatory t-cells for the augmentation of cancer immunotherapy","volume":"8","author":"Schabowsky","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16313","article-title":"The impact of foxp3(+) regulatory t-cells on cd8(+) t-cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors","volume":"183","author":"Attias","year":"2026","journal-title":"Br J Pharmacol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207609","article-title":"Transcriptional activation of c-myc proto-oncogene by wt1 protein","volume":"23","author":"Han","year":"2004","journal-title":"Oncogene"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyp194","article-title":"Wt1 (wilms' tumor gene 1): biology and cancer immunotherapy","volume":"40","author":"Sugiyama","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.11377","article-title":"Comprehensive analysis based on dna methylation and rna-seq reveals hypermethylation of the up-regulated wt1 gene with potential mechanisms in pam50 subtypes of breast cancer","volume":"9","author":"Ren","year":"2021","journal-title":"PeerJ"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2019.12.002","article-title":"Expression of tumor-associated antigens in breast cancer subtypes","volume":"49","author":"Curigliano","year":"2020","journal-title":"Breast"},{"key":"B126","article-title":"Wilms' tumor suppressor gene (wt1) is expressed in primary breast tumors despite tumor-specific promoter methylation","volume":"61","author":"Loeb","year":"2001","journal-title":"Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/bf02982573","article-title":"The role of wt1 in oncogenesis: tumor suppressor or oncogene","volume":"76","author":"Loeb","year":"2002","journal-title":"Int J Hematol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.15.8132","article-title":"Altered expression of the wt1 wilms tumor suppressor gene in human breast cancer","volume":"94","author":"Silberstein","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B129","article-title":"The wilms' tumor suppressor wt1 inhibits Malignant progression of neoplastigenic mammary epithelial cells","volume":"28","author":"Wang","year":"2008","journal-title":"Anticancer Res"},{"key":"B130","article-title":"Promoter methylation and mrna expression of wt1 gene in mcf10 breast cancer model","volume":"36","author":"Yang","year":"2007","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404624","article-title":"A tumor suppressor and oncogene: the wt1 story","volume":"21","author":"Yang","year":"2007","journal-title":"Leukemia"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068837","article-title":"Wt1 promotes cell proliferation in non-small cell lung cancer cell lines through up-regulating cyclin d1 and p-prb in vitro and in vivo","volume":"8","author":"Xu","year":"2013","journal-title":"PloS One"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3892\/or.2012.1906","article-title":"High wilms' tumor 1 mrna expression correlates with basal-like and erbb2 molecular subtypes and poor prognosis of breast cancer","volume":"28","author":"Qi","year":"2012","journal-title":"Oncol Rep"},{"key":"B134","article-title":"High expression of wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients","volume":"8","author":"Miyoshi","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0317-1","article-title":"Wt1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer","volume":"119","author":"McGregor","year":"2018","journal-title":"Br J Cancer"},{"key":"B136","article-title":"Correlation of wilms' tumor 1 isoforms with her2 and er-\u03b1 and its oncogenic role in breast cancer","volume":"34","author":"Nasomyon","year":"2014","journal-title":"Anticancer Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208345","article-title":"Her2\/neu increases the expression of wilms' tumor 1 (wt1) protein to stimulate s-phase proliferation and inhibit apoptosis in breast cancer cells","volume":"24","author":"Tuna","year":"2005","journal-title":"Oncogene"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000739","article-title":"The wilms' tumor suppressor wt1 induces estrogen-independent growth and anti-estrogen insensitivity in er-positive breast cancer mcf7 cells","volume":"23","author":"Wang","year":"2010","journal-title":"Oncol Rep"},{"key":"B139","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/bctt.s392480","article-title":"Transcriptome profiling analysis of breast cancer cell mcf-7 treated by sesamol","volume":"15","author":"Wu","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210622","article-title":"Wilms' tumor protein 1: an early target of progestin regulation in t-47d breast cancer cells that modulates proliferation and differentiation","volume":"27","author":"Caldon","year":"2008","journal-title":"Oncogene"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185565","article-title":"Microrna-193a inhibits breast cancer proliferation and metastasis by downregulating wt1","volume":"12","author":"Xie","year":"2017","journal-title":"PloS One"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1743","article-title":"The zinc finger domain of wilms' tumor 1 suppressor gene (wt1) behaves as a dominant negative, leading to abrogation of wt1 oncogenic potential in breast cancer cells","volume":"9","author":"Han","year":"2007","journal-title":"Breast Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22446","article-title":"A zbtb7a proto-oncogene as a novel target for mir-125a","volume":"55","author":"Hojo","year":"2016","journal-title":"Mol Carcinog"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-291x(02)00751-9","article-title":"Downregulation of wilms' tumor 1 protein inhibits breast cancer proliferation","volume":"295","author":"Zapata-Benavides","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s12291-022-01053-9","article-title":"Correlation of wilms' tumor 1 (wt1) with oxidative stress markers and expression of mir-361-5p; new aspect of wt1 in breast cancer","volume":"38","author":"Pishbin","year":"2023","journal-title":"Indian J Clin Biochem"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1677\/jme.1.01761","article-title":"The wt1 wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates igf-i receptor gene transcription in breast cancer cells","volume":"35","author":"Reizner","year":"2005","journal-title":"J Mol Endocrinol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2006.03.018","article-title":"Transcriptional regulation of the insulin-like growth factor-i receptor gene in breast cancer","volume":"252","author":"Sarfstein","year":"2006","journal-title":"Mol Cell Endocrinol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1177\/030089161309900612","article-title":"Insulin-like growth factor i regulates the expression of isoforms of wilms' tumor 1 gene in breast cancer","volume":"99","author":"Tuna","year":"2013","journal-title":"Tumori"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/srep45255","article-title":"Wt1 expression in breast cancer disrupts the epithelial\/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel","volume":"7","author":"Artibani","year":"2017","journal-title":"Sci Rep"},{"key":"B150","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/jcm8040439","article-title":"Epithelial to mesenchymal transition and cell biology of molecular regulation in endometrial carcinogenesis","volume":"8","author":"Chiu","year":"2019","journal-title":"J Clin Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5837","article-title":"A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0376-2491.2016.44.005","article-title":"Effect of single nucleotide polymorphisms of RS1799937 located in WT1 gene on the pathlogical complete response to neoadjuvant chemotherapy in breast cancer patients","volume":"96","author":"Li","year":"2016","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6282514","article-title":"Truncated WT1 protein isoform expression is increased in MCF-7 cells with long-term estrogen depletion","volume":"2021","author":"Santiago","year":"2021","journal-title":"Int J Breast Cancer"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-07-2179","article-title":"Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells","volume":"6","author":"Han","year":"2008","journal-title":"Mol Cancer Res"},{"key":"B155","article-title":"Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin","volume":"23","author":"Zhang","year":"2003","journal-title":"Anticancer Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2011.250","article-title":"Opposite regulation of estrogen receptor-\u03b1 and its variant ER-\u03b136 by the Wilms' tumor suppressor WT1","volume":"2","author":"Kang","year":"2011","journal-title":"Oncol Lett"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.04.009","article-title":"WT1 peptide vaccine for the treatment of cancer","volume":"20","author":"Oka","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.ccr-05-1483","article-title":"Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer","volume":"12","author":"Gillmore","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.2217\/imt.10.58","article-title":"WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects","volume":"2","author":"Oka","year":"2010","journal-title":"Immunotherapy"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2296735","article-title":"Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives","volume":"20","author":"Ogasawara","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.2174\/187152009789056958","article-title":"WT1 peptide vaccine as a paradigm for \"cancer antigen-derived peptide\"-based immunotherapy for Malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide","volume":"9","author":"Oka","year":"2009","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"B162","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/cancers16050981","article-title":"Dendritic cells in cancer immunology and immunotherapy.","volume":"16","author":"Hato","year":"2024","journal-title":"Cancers (Bsl)"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800588","article-title":"Immunohistochemical detection of WT1 protein in a variety of cancer cells","volume":"19","author":"Nakatsuka","year":"2006","journal-title":"Mod Pathol"},{"key":"B164","article-title":"Immunohistochemical analysis of WT1 antigen expression in various solid cancer cells","volume":"36","author":"Naitoh","year":"2016","journal-title":"Anticancer Res"},{"key":"B165","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.3.1036","article-title":"Distinct dendritic cell subsets differentially regulate the class of immune response in vivo","volume":"96","author":"Pulendran","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.3.587","article-title":"CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo","volume":"189","author":"Maldonado-L\u00f3pez","year":"1999","journal-title":"J Exp Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.963424","article-title":"Trial watch: Dendritic cell-based anticancer therapy","volume":"3","author":"Bloy","year":"2014","journal-title":"Oncoimmunology"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0031","article-title":"Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer","volume":"8","author":"Koido","year":"2016","journal-title":"Immunotherapy"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-002-0328-9","article-title":"Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues","volume":"51","author":"Tsuboi","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann Oncol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31953-x","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2310","article-title":"Response rate and safety of a neoadjuvant pertuzumab, atezolizumab, docetaxel, and trastuzumab regimen for patients with ERBB2-positive stage II\/III breast cancer: The Neo-PATH phase 2 nonrandomized clinical trial","volume":"8","author":"Ahn","year":"2022","journal-title":"JAMA Oncol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41523-022-00500-3","article-title":"A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013","volume":"8","author":"Ademuyiwa","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2023.01.001","article-title":"Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041)","volume":"184","author":"Fasching","year":"2023","journal-title":"Eur J Cancer"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat Med"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-06929-9","article-title":"A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer","volume":"199","author":"Yam","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B182","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","article-title":"PD-L1 degradation pathway and immunotherapy for cancer","volume":"11","author":"Gou","year":"2020","journal-title":"Cell Death Dis"},{"key":"B183","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.3390\/cancers14163860","article-title":"Modern immunotherapy in the treatment of triple-negative breast cancer","volume":"14","author":"Wesolowski","year":"2022","journal-title":"Cancers (Bsl)"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discov"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.07.006","article-title":"PD-1\/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer","volume":"25","author":"Zhu","year":"2020","journal-title":"Drug Discov Today"},{"key":"B186","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41416-018-0297-1","article-title":"Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease","volume":"120","author":"Wu","year":"2019","journal-title":"Br J Cancer"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-3001","article-title":"Breast cancer immunotherapy: Facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-2260","article-title":"Neoadjuvant chemotherapy and immunotherapy in luminal B-like breast cancer: Results of the phase II GIADA trial","volume":"28","author":"Dieci","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B189","doi-asserted-by":"publisher","first-page":"6654","DOI":"10.1038\/s41467-023-42479-w","article-title":"Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"B190","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0607","article-title":"Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1\/L1 therapy in patients with HER2-negative primary breast cancer","volume":"27","author":"Gonzalez-Ericsson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1732211","article-title":"Atezolizumab for the treatment of breast cancer","volume":"20","author":"Reddy","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab121","article-title":"Determining PD-L1 status in patients with triple-negative breast cancer: Lessons learned from IMpassion130","volume":"114","author":"Badve","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"B194","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11864-021-00833-4","article-title":"Biomarkers of immune checkpoint blockade response in triple-negative breast cancer","volume":"22","author":"Isaacs","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32517-x","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1647","article-title":"KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41523-023-00579-2","article-title":"Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer","volume":"9","author":"Fabi","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B202","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02772","article-title":"Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: Primary results of the randomized phase III IMpassion050 trial","volume":"40","author":"Huober","year":"2022","journal-title":"J Clin Oncol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2023011","article-title":"Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis","volume":"22","author":"Latif","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02126-1","article-title":"Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial","volume":"28","author":"R\u00f8ssevold","year":"2022","journal-title":"Nat Med"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.04.011","article-title":"Impact of anti-HER2 treatments combined with atezolizumab on the tumor immune microenvironment in early or metastatic breast cancer: Results from a phase Ib study","volume":"21","author":"Hamilton","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005573","article-title":"Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types","volume":"10","author":"Maule","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3690","article-title":"Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: An analysis of data from the I-SPY2 randomized clinical trial","volume":"7","author":"Symmans","year":"2021","journal-title":"JAMA Oncol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02736-z","article-title":"Pembrolizumab and atezolizumab in triple-negative breast cancer","volume":"70","author":"Kwapisz","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B215","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12967-020-02424-7","article-title":"ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer","volume":"18","author":"Kyte","year":"2020","journal-title":"J Transl Med"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01331-y","article-title":"Optimization of neoadjuvant therapy for early-stage triple-negative and HER2\u2009+\u2009breast cancer","volume":"24","author":"Phadke","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.3233\/bd-229001","article-title":"Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report","volume":"41","author":"Kharel","year":"2022","journal-title":"Breast Dis"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102459","article-title":"Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences","volume":"110","author":"Bonadio","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1110","article-title":"FDA approval summary: Pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer","volume":"28","author":"Shah","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2265059","article-title":"The role of immune checkpoint inhibition in triple negative breast cancer","volume":"23","author":"Tarekegn","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13267-z","article-title":"Preoperative immunotherapy combined with chemotherapy for triple-negative breast cancer: Perspective on the KEYNOTE-522 study","volume":"30","author":"Downs-Canner","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: An analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"key":"B227","doi-asserted-by":"publisher","first-page":"Of6","DOI":"10.1158\/2159-8290.cd-nd2020-009","article-title":"Neoadjuvant immunotherapy: Making strides","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2535","article-title":"Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: Three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial","volume":"6","author":"Yee","year":"2020","journal-title":"JAMA Oncol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.610149","article-title":"Case report: Long-term response to pembrolizumab combined with endocrine therapy in metastatic breast cancer patients with hormone receptor expression","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.575978","article-title":"PELICAN-IPC 2015-016\/Oncodistinct-003: A prospective, multicenter, open-label, randomized, non-comparative, phase II study of pembrolizumab in combination with neo adjuvant EC-paclitaxel regimen in HER2-negative inflammatory breast cancer","volume":"10","author":"Bertucci","year":"2020","journal-title":"Front Oncol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz158","article-title":"Corrigendum to \"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study\": [Annals of Oncology (2019), volume 30:1279-1288","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"key":"B234","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: Results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.008","article-title":"I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment","volume":"39","author":"Perez-Garcia","year":"2021","journal-title":"Cancer Cell"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00219-7","article-title":"Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide in triple-negative breast cancer","volume":"7","author":"Foldi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B237","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41523-022-00392-3","article-title":"Author correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide in triple-negative breast cancer","volume":"8","author":"Foldi","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3215","article-title":"Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide in basal-like triple-negative breast cancer","volume":"28","author":"Blenman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-1303","article-title":"PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple-negative breast cancer","volume":"26","author":"Ahmed","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0862","article-title":"Clinical outcomes and immune markers by race in a phase I\/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC","volume":"28","author":"Foldi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11912-018-0701-2","article-title":"Checkpoint inhibitors in the treatment of breast cancer","volume":"20","author":"Lyons","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9256","article-title":"Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab","volume":"7","author":"Fujii","year":"2016","journal-title":"Oncotarget"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02140","article-title":"Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against triple negative breast cancer cells","volume":"9","author":"Juli\u00e1","year":"2018","journal-title":"Front Immunol"},{"key":"B245","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3390\/cancers14143361","article-title":"CDK inhibition primes for anti-PD-L1 treatment in triple-negative breast cancer models","volume":"14","author":"Cheung","year":"2022","journal-title":"Cancers (Bsl)"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: Results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103464","article-title":"Efficacy and safety profile of avelumab monotherapy","volume":"166","author":"Zhao","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B249","doi-asserted-by":"publisher","first-page":"e130688","DOI":"10.1172\/jci.insight.130688","article-title":"Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK","volume":"4","author":"Giles","year":"2019","journal-title":"JCI Insight"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B251","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12032-018-1228-y","article-title":"Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer","volume":"36","author":"La Rocca","year":"2018","journal-title":"Med Oncol"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2049232","article-title":"Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer","volume":"31","author":"Agostinetto","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"B253","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11912-020-00944-5","article-title":"The role of neoadjuvant therapy in melanoma","volume":"22","author":"Kelly","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0020","article-title":"Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: a case report","volume":"12","author":"Billena","year":"2020","journal-title":"Immunotherapy"},{"key":"B255","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-024-46961-x","article-title":"Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study","volume":"15","author":"Lynce","year":"2024","journal-title":"Nat Commun"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01543-z","article-title":"Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models","volume":"31","author":"Zheng","year":"2024","journal-title":"Breast Cancer"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.103580","article-title":"Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8","volume":"72","author":"Jerusalem","year":"2023","journal-title":"Breast"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-23-0145","article-title":"A pilot study of neoadjuvant nivolumab, ipilimumab, and intralesional oncolytic virotherapy for HER2-negative breast cancer","volume":"3","author":"Nguyen","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09684-8","article-title":"The emerging role of transcription factor FOXP3 in thyroid cancer","volume":"23","author":"Gong","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.07.022","article-title":"FoxP3(+) T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets","volume":"490","author":"Saleh","year":"2020","journal-title":"Cancer Lett"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201847659","article-title":"Targeting Treg cells in cancer immunotherapy","volume":"49","author":"Tanaka","year":"2019","journal-title":"Eur J Immunol"},{"key":"B263","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10549-010-0831-1","article-title":"Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy","volume":"125","author":"Ladoire","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24125","article-title":"FOXP3 expression in tumor cells and implications for cancer progression","volume":"228","author":"Triulzi","year":"2013","journal-title":"J Cell Physiol"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.32604\/or.2022.025249","article-title":"Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (ex-vivo study)","volume":"29","author":"El-Houseini","year":"2021","journal-title":"Oncol Res"},{"key":"B266","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-020-05819-8","article-title":"Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+\u2009and FOXP3+\u2009immune cells in HER2-positive breast cancer treated with neoadjuvant therapies","volume":"183","author":"Zhao","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01065-3","article-title":"Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1","volume":"123","author":"Kalaw","year":"2020","journal-title":"Br J Cancer"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3197-y","article-title":"Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy","volume":"148","author":"Miyashita","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1159\/000351473","article-title":"FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph node-positive breast cancer patients","volume":"85","author":"Kim","year":"2013","journal-title":"Oncology"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106087","article-title":"Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target","volume":"78","author":"Hashemi","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.781400","article-title":"Epigenetic alteration and its association with downregulated FOXP3 gene in Indian breast cancer patients","volume":"12","author":"Sadaf","year":"2021","journal-title":"Front Genet"},{"key":"B272","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.3390\/cancers14092138","article-title":"The effect of intratumoral interrelation among FOXP3+ regulatory T cells on treatment response and survival in triple-negative breast cancer","volume":"14","author":"Goda","year":"2022","journal-title":"Cancers (Bsl)"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01049-4","article-title":"The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer","volume":"27","author":"Goto","year":"2020","journal-title":"Breast Cancer"},{"key":"B274","article-title":"Regulating regulatory T cells to achieve transplant tolerance","volume":"6","author":"Tao","year":"2007","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23169","article-title":"HDAC inhibition potentiates immunotherapy in triple negative breast cancer","volume":"8","author":"Terranova-Barberio","year":"2017","journal-title":"Oncotarget"},{"key":"B276","doi-asserted-by":"publisher","first-page":"e003892","DOI":"10.1136\/jitc-2021-003892","article-title":"Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer","volume":"10","author":"Revenko","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B277","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-021-01472-x","article-title":"Dual CRISPR interference and activation for targeted reactivation of X-linked endogenous FOXP3 in human breast cancer cells","volume":"21","author":"Cui","year":"2022","journal-title":"Mol Cancer"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-021-03126-1","article-title":"Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8\u2009+\u2009and regulatory FOXP3\u2009+\u2009cells tumor-associated infiltrate and other prognostic factors","volume":"479","author":"Glajcar","year":"2021","journal-title":"Virchows Arch"},{"key":"B279","article-title":"Efficacy of WT1 peptide-\/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers","volume":"41","author":"Kato","year":"2014","journal-title":"Gan To Kagaku Ryoho"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyl005","article-title":"A phase I\/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid Malignancy: safety assessment based on the phase I data","volume":"36","author":"Morita","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"B281","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000437183","article-title":"Immunotherapy of breast cancer","volume":"42","author":"Criscitiello","year":"2015","journal-title":"Prog Tumor Res"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1007\/bf02982574","article-title":"Cancer immunotherapy targeting WT1 protein","volume":"76","author":"Sugiyama","year":"2002","journal-title":"Int J Hematol"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2021-207464","article-title":"Clinicopathological significance of WT1 expression in invasive breast carcinoma with >90% mucinous component","volume":"75","author":"Xu","year":"2022","journal-title":"J Clin Pathol"},{"key":"B284","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.humpath.2023.01.005","article-title":"WT1 as a myoepithelial marker: a comparative study of breast, cutaneous, and salivary gland lesions","volume":"135","author":"Ng","year":"2023","journal-title":"Hum Pathol"},{"key":"B285","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1186\/s12885-020-07183-8","article-title":"Methylation of WT1, CA10 in peripheral blood leukocyte is associated with breast cancer risk: a case-control study","volume":"20","author":"Ge","year":"2020","journal-title":"BMC Cancer"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-003-0498-0","article-title":"WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone","volume":"53","author":"Nakajima","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2257-2","article-title":"Phase I\/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer","volume":"68","author":"Zhang","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4130-y","article-title":"Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II\/III breast cancer: a randomized Phase I study","volume":"162","author":"Higgins","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B290","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12935-023-02941-7","article-title":"Comparative efficacy and safety of PD-1\/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials","volume":"23","author":"Elmakaty","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B291","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1016\/j.clbc.2024.08.005","article-title":"Detrimental impact of chemotherapy dose reduction or discontinuation in early stage triple-negative breast cancer treated with pembrolizumab and neoadjuvant chemotherapy: a multicenter experience","volume":"24","author":"Krishnan","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"B292","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/cancers18030358","article-title":"Neoadjuvant pembrolizumab associated with chemotherapy in early triple-negative breast cancer patients: real-world data from a French single-center experience","volume":"18","author":"Ben Abdallah","year":"2026","journal-title":"Cancers (Bsl)"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2025.100157","article-title":"Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer","volume":"9","author":"Arnaud","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"B294","doi-asserted-by":"publisher","first-page":"PS14-03","DOI":"10.1158\/1538-7445.sabcs23-ps14-03","article-title":"Abstract PS14-03: Delayed and post-treatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors","volume":"84","author":"Jacob","year":"2024","journal-title":"Cancer Res"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111961","article-title":"Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: a systematic review and meta-analysis","volume":"133","author":"Yang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.35.15_suppl.e20647","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"B299","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B301","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/jcm12030953","article-title":"Predictive biomarkers for response to immunotherapy in triple negative breast cancer: promises and challenges","volume":"12","author":"Wang","year":"2023","journal-title":"J Clin Med"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0450","article-title":"Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study","volume":"12","author":"Friedman","year":"2022","journal-title":"Cancer Discov"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"Jama"},{"key":"B304","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","article-title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030","volume":"34","author":"Parsons","year":"2023","journal-title":"Ann Oncol"},{"key":"B305","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B307","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-4070","article-title":"FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat Immunol"},{"key":"B309","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"B312","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"B313","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","article-title":"Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer","volume":"182","author":"Katzenelenbogen","year":"2020","journal-title":"Cell"},{"key":"B314","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919882581","article-title":"Controversial issues in the neoadjuvant treatment of triple-negative breast cancer","volume":"11","author":"Fitzpatrick","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B315","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1038\/s41467-020-17414-y","article-title":"Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer","volume":"11","author":"Terranova-Barberio","year":"2020","journal-title":"Nat Commun"},{"key":"B316","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0429-7","article-title":"Connecting blood and intratumoral T(reg) cell activity in predicting future relapse in breast cancer","volume":"20","author":"Wang","year":"2019","journal-title":"Nat Immunol"},{"key":"B317","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac098","article-title":"Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)","volume":"52","author":"Saji","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"B318","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41523-022-00457-3","article-title":"Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer","volume":"8","author":"Barrios","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B319","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"B320","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.3390\/cancers15184479","article-title":"Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: A review of current evidence and prognostic implications from pathologist's perspective","volume":"15","author":"Angelico","year":"2023","journal-title":"Cancers (Bsl)"},{"key":"B321","doi-asserted-by":"publisher","DOI":"10.31557\/apjcp.2022.23.6.2095","article-title":"Expression of PD-L1 in locally advanced breast cancer and its impact on neoadjuvant chemotherapy response","volume":"23","author":"Hussein","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"B322","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: Results from phase 1 of the Blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B323","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13058-019-1156-6","article-title":"Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer","volume":"21","author":"Rimm","year":"2019","journal-title":"Breast Cancer Res"},{"key":"B324","doi-asserted-by":"publisher","first-page":"e011258","DOI":"10.1136\/jitc-2024-011258","article-title":"Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee","volume":"13","author":"Dent","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B325","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103261","article-title":"Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer","volume":"84","author":"Tay-Teo","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B326","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"Bmj"},{"key":"B327","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.088","article-title":"Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions","volume":"33","author":"Bianchini","year":"2022","journal-title":"Ann Oncol"},{"key":"B328","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/cancers14030482","article-title":"Molecular targets of triple-negative breast cancer: Where do we stand","volume":"14","author":"Newton","year":"2022","journal-title":"Cancers (Bsl)"},{"key":"B329","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0701","article-title":"Facts and hopes in immunotherapy for early-stage triple-negative breast cancer","volume":"29","author":"Nederlof","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B330","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102669","article-title":"Neoadjuvant therapy in hormone receptor-positive\/HER2-negative breast cancer","volume":"123","author":"Cantini","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B331","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.3390\/cancers12082081","article-title":"The changing paradigm for the treatment of HER2-positive breast cancer","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers (Bsl)"},{"key":"B332","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3390\/cancers13071655","article-title":"Immune checkpoint blockade in HER2-positive breast cancer: What role in early disease setting","volume":"13","author":"Solinas","year":"2021","journal-title":"Cancers (Bsl)"},{"key":"B333","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/jpm13030526","article-title":"Immunotherapy targeting PD-1\/PD-L1 in early-stage triple-negative breast cancer","volume":"13","author":"Yang","year":"2023","journal-title":"J Pers Med"},{"key":"B334","doi-asserted-by":"publisher","DOI":"10.1039\/d1nr06577g","article-title":"Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers","volume":"14","author":"Atukorale","year":"2022","journal-title":"Nanoscale"},{"key":"B335","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221146129","article-title":"Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives","volume":"15","author":"Valenza","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B336","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104309","article-title":"Clinical characteristics associated with efficacy and prognosis among patients treated with PD-1\/PD-L1 inhibitors for early-stage triple-negative breast cancers: A meta-analysis","volume":"196","author":"Wei","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B337","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000000675","article-title":"Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer","volume":"32","author":"Chan","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"B338","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/cancers13040746","article-title":"PD-L1 expression after neoadjuvant chemotherapy in triple-negative breast cancers is associated with aggressive residual disease, suggesting a potential for immunotherapy","volume":"13","author":"Grandal","year":"2021","journal-title":"Cancers (Bsl)"},{"key":"B339","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103713","article-title":"Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer","volume":"9","author":"Quintana","year":"2024","journal-title":"ESMO Open"},{"key":"B340","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/nejmoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B341","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"key":"B342","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02210-0","article-title":"Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial","volume":"29","author":"Soliman","year":"2023","journal-title":"Nat Med"},{"key":"B343","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02170","article-title":"Breast cancers are immunogenic: Immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes","volume":"40","author":"Zacharakis","year":"2022","journal-title":"J Clin Oncol"},{"key":"B344","doi-asserted-by":"publisher","first-page":"e011533","DOI":"10.1136\/jitc-2025-011533","article-title":"B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer","volume":"13","author":"Stucchi","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B345","doi-asserted-by":"publisher","first-page":"28","DOI":"10.21037\/cco.2020.04.01","article-title":"Prospect of immunotherapy in neoadjuvant\/adjuvant treatment for early breast cancer","volume":"9","author":"Miyashita","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B346","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"B347","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04278-5","article-title":"Multi-omic machine learning predictor of breast cancer therapy response","volume":"601","author":"Sammut","year":"2022","journal-title":"Nature"},{"key":"B348","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02857-3","article-title":"Towards a general-purpose foundation model for computational pathology","volume":"30","author":"Chen","year":"2024","journal-title":"Nat Med"},{"key":"B349","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1350935","article-title":"Patient-derived organoids: a promising tool for breast cancer research","volume":"14","author":"Shi","year":"2024","journal-title":"Front Oncol"},{"key":"B350","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00375-0","article-title":"Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity","volume":"3","author":"Tsai","year":"2022","journal-title":"Nat Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1851289\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:09:19Z","timestamp":1786360159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1851289\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":350,"alternative-id":["10.3389\/fimmu.2026.1851289"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1851289","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1851289"}}